Neuroendocrine prostate cancer cells from a patient biopsy.
Courtesy of Dr. Loredana Puca.

Weill Cornell Medicine has been awarded a five-year, $11.3 million Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute to improve the detection, diagnosis, and treatment of prostate cancer.

Established in 1992, SPORE grants serve as the cornerstone of the NCI’s efforts to promote collaborative, interdisciplinary translational cancer research. This SPORE grant is the first ever awarded to Weill Cornell Medicine and will expand an already vibrant prostate cancer basic and translational research program at the institution’s Sandra and Edward Meyer Cancer Center and Caryl and Israel Englander Institute for Precision Medicine.

“This prestigious grant will enable us to enhance our innovative, translational research into prostate cancer and inspire new collaborations as we work together to find a cure for this disease,” says Augustine M.K. Choi, MD, the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine. “The team of SPORE investigators is exceptional and its groundbreaking work will undoubtedly advance our mission of scientific discovery and patient care, reinforcing Weill Cornell Medicine’s reputation as a leader in research.”